Amit Etkin | BiotechTV

top of page

Search

Alto Neuroscience's CEO on today's $128.6 million NYSE IPO

Alto Neuroscience's CEO on today's $128.6 million NYSE IPO

Alto Neuroscience's CEO on today's $128.6 million NYSE IPO

Amit Etkin describes Alto's approach to tyring to bring precision medicine to psychiatry.

Feb 2, 2024

Alto Neuroscience's CEO on why MDD data at #ACNP2023 may validate its precision medicine approach

Alto Neuroscience's CEO on why MDD data at #ACNP2023 may validate its precision medicine approach

Alto Neuroscience's CEO on why MDD data at #ACNP2023 may validate its precision medicine approach

Amit Etkin says that psychiatric conditions have been treated too broadly in the past.

Dec 4, 2023

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

Allucent Clinical Research Organization™ is on a mission to help bring new therapies to light by solving the distinct challenges of small and mid-sized biotech companies. We’re a global provider of comprehensive drug development solutions, including consulting, clinical operations, biometrics, and clinical pharmacology across a variety of therapeutic areas.

Learn more about Allucent

bottom of page